A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Trial Profile

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs SB 623 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ACTISSIMA
  • Sponsors SanBio
  • Most Recent Events

    • 01 Apr 2018 According to a SanBio media release, results are expected to be published by July 2019 after 12-month follow-up period.
    • 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Jul 2017 According to a SanBio Inc. media release, enrollment in this trial is expected to be complete in March 2018 and results are expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top